# VTA VGluT2 Sociability Circuit in Genetic Autism

> **NIH NIH R01** · BETH ISRAEL DEACONESS MEDICAL CENTER · 2020 · $437,500

## Abstract

PROJECT SUMMARY
Autism spectrum disorder (ASD) is characterized by its deficits in social interactions. Oxytocin is a
hypothalamic neuropeptide known to increase social interactions through its oxytocin receptor (Oxtr) but where
this occurs remains undefined. Maternal 15q11-13 triplications (extranumerary isodicentric chromosome 15,
idic15) cause a highly penetrant autism that we have linked to the increased dosage of UBE3A. UBE3A
encodes an ubiquitin-ligase and transcriptional co-regulator expressed exclusively from the maternal allele in
mature neurons. Seizures are a frequent comorbidity in ASD including in idic15. In our recent study (Krishnan
et al. Nature 2017), we established that a previously enigmatic population of glutamatergic neurons in the
brainstem ventral tegmental area (VTA) drives sociability and found increases of UBE3A and seizures
converge to repress expression of autism network gene Cbln1 to impair sociability within these neurons. In
Aim 1, we investigate a new concept, that oxytocin receptors mark the specific population of VTA
glutamatergic neurons that promote sociability and that oxytocin receptor activity in these neurons is necessary
for normal sociability. In Aim 2, we investigate the target site where VTA glutamatergic neurons promote
sociability by testing if chemogenetically-controlled activity and Grid1 expression (Cbln1's postsynaptic binding
partner that is deleted in autism) in the nucleus accumbens are necessary and sufficient to promote sociability.
VTA glutamatergic neurons form excitatory synapses onto nucleus accumbens neurons and we have shown
these synapses are impaired by Cbln1 deletion and by seizures. In Aim 3, we test if increases of UBE3A and
seizures converge on the specific VTA glutamatergic neurons that express oxytocin receptors to impair
sociability and glutamategic transmission if these defects can rescued by adding back Cbln1 to these
specialized neurons. In Aim 4, we investigate whether in vivo chemogenetic increases of oxytocin signaling
can rescue the VTA glutamatergic neuron to nucleus accumbens synaptic defects and sociability impairments
produced by increased UBE3A and seizures. In this study, we combine conditional mouse genetics,
stereotaxic viral vector-based gene deliveries methods including VGluT2 and Oxtr promoter intersectional
genetics, behavioral chemogenetics, and brain slice optogenetics electrophysiology techniques to uncover a
convergent molecular autism gene network and neuronal circuitry where three models of human autism
spectrum disorder impair sociability. (1) Increased Ube3a gene dosage (maternal 15q11-13 triplication) and (2)
epilepsy convergence to repress Cbln1 in VTA glutamatergic neurons and (3) loss of Grid1, Cbln1's
postsynaptic binding partner in nucleus accumbens all impair sociability. We also perform a series of in vivo
preclinical tests of the efficacy of therapeutic interventions using viral vector-based methods aimed at these
molecules and circuits and t...

## Key facts

- **NIH application ID:** 9856154
- **Project number:** 5R01MH112714-03
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **Principal Investigator:** MATTHEW P ANDERSON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $437,500
- **Award type:** 5
- **Project period:** 2018-05-01 → 2023-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9856154

## Citation

> US National Institutes of Health, RePORTER application 9856154, VTA VGluT2 Sociability Circuit in Genetic Autism (5R01MH112714-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9856154. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*